Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Occult Blood Test Increases Colon Cancer Screenings

By LabMedica International staff writers
Posted on 13 Aug 2013
A new study suggests that noninvasive fecal immunochemical tests (FIT) might be more effective in prompting participation in potentially lifesaving colorectal cancer (CRC) screening than colonoscopy, a more expensive and invasive procedure.

Researchers at UT Southwestern (Dallas, TX, USA) and the University of California, San Diego (UCSD, USA) identified 5,970 uninsured (undeserving) patients who were not up to date with CRC screening. More...
Mean patient age was 59 years, and 64% of patients were women. The sample populations was classified as 41% white, 24% black, 29% Hispanic, and 7% other race/ethnicity. The patients were subsequently assigned randomly to three groups.

One group was assigned to FIT outreach, consisting of mailed invitation to use and return an enclosed no-cost FIT (1,593 patients). A second was assigned to colonoscopy outreach, consisting of mailed invitation to schedule a no-cost colonoscopy (479 patients). The third group was assigned to usual care, consisting of opportunistic primary care visit–based screening (3,898 patients). In addition, the FIT and colonoscopy outreach groups received telephone follow-up to promote test completion. The main outcome measures were screening participation in any CRC test within one year.

The results showed that screening participation was significantly higher for both FIT (40.7%) and colonoscopy outreach (24.6%) groups than for usual care (12.1%). On analysis, screening was higher higher for FIT than for colonoscopy outreach among whites, blacks, and Hispanics. Rates of CRC identification and advanced adenoma detection were 0.4% and 0.8% for FIT outreach, 0.4%, and 1.3% for colonoscopy outreach, and 0.2% and 0.4% for usual care, respectively. Eleven of 60 patients with abnormal FIT results did not complete colonoscopy. The study was published in the August 5, 2013, edition of JAMA Internal Medicine.

“The study suggests that the best approach to offering and delivering screening to underserved populations may be through FIT,” said senior author Celette Sugg Skinner, MD, associate director of population science and cancer control at the UT Southwestern Cancer Center. “Questions for the future are whether superior participation can be maintained in the FIT group (because the test must be repeated every year) and how adherence rates will impact overall screening effectiveness and cost.”

FIT is a quick and easy test that requires no special preparation that is used to detect small amounts of occult blood in a patient's stool sample. Completed tests are then mailed to a laboratory for analysis.

Related Links:

UT Southwestern
University of California, San Diego



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
HPV Test
Allplex HPV28 Detection
Gold Member
Aspiration System
VACUSAFE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Measuring six variants from one sample may improve research efficiency and support clinical trials of amyloid biology in Alzheimer’s disease and related conditions (Image Credit: Adobe Stock)

Plasma Assay Measures Six Amyloid Beta Peptides for Alzheimer’s Treatment Research

Alzheimer’s disease research and related neurological studies often require tools that can characterize brain amyloid pathology and amyloid beta biology. Blood-based biomarker assays may help researchers... Read more

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.